Celcuity Inc (CELC) Stock Price, Quote & News

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology

Sector: Healthcare

Phone: 763 392 0767

Website: www.celcuity.com

Address:

16305 36th Avenue North, Suite 100, Minneapolis, United States

CharlieeMungerTWITS Feb. 21 at 1:20 AM

$CELC I’m coming I’m coming baby. Don’t worry

0 · Reply

Savon13 Feb. 18 at 3:58 PM

$IBRX feels good to be in under $6. Hoping this goes the same way as $CELC

1 · Reply

DipinDipout Feb. 17 at 9:50 PM

$CELC keep these SLS garbage posts out of here! Those folks are sooooo desperate, avoid at all costs! Bunch of kids hoping to be billionaires while snacking in their parents basements!

1 · Reply

WallStreetBuyDip Feb. 16 at 11:25 PM

Comparing trending tickers $CELC vs $COMP: CELC is currently priced at $104.51, showing a slight decrease of 0.34%, with today’s trading volume at 407.7K, which is below its average of 814.2K. In contrast, COMP is up by 0.87% at $10.41, with a significantly high trading volume of 17.4M, well above its usual 11.3M. While COMP is experiencing stronger buying interest and a positive price change, CELC seems to be lagging slightly, with a minor dip in price and less trading activity compared to its average.

0 · Reply

WallStreetBuyDip Feb. 16 at 10:59 PM

Comparing trending tickers $CHAC vs $CELC: CHAC slightly rose by 0.19% to $10.50 on a volume of 229.9K, which is below its average volume of 280.7K. In contrast, CELC dipped by 0.34% to $104.51 with a trading volume of 407.7K, notably lower than its usual 814.2K. While both stocks showed modest changes in price, CELC experienced a larger drop in volume relative to its average, indicating softer trading activity compared to CHAC.

0 · Reply

BIOTECH_GURU Feb. 16 at 8:00 PM

$CELC this is how i feel about $SLS Lots of upside potential. Hoping for $50 will take $25.

2 · Reply

UgoGreg Feb. 16 at 7:27 PM

$CELC https://youtu.be/ygBN8MilTyc

0 · Reply

Florestan Feb. 16 at 12:54 PM

$CELC time flies eh?

0 · Reply

Dark_Horse_Investments Feb. 13 at 9:33 PM

$CELC Key board member added, Charles Romp. Laying the tracks for a possible transaction. He was part in the sale of Seattle Genetics to $PFE ( owned the former & own latter ). Per q4-25 13-f PFE owns 349K CELC shares. https://ir.celcuity.com/news-releases/news-release-details/celcuity-appoints-charles-romp-its-board-directors

0 · Reply

SuperGreenToday Feb. 12 at 12:40 AM

$CELC Share Price: $104.14 Contract Selected: May 15, 2026 $105 Calls Buy Zone: $13.43 – $16.59 Target Zone: $24.96 – $30.50 Potential Upside: 76% ROI Time to Expiration: 92 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 12, 2026, 4:05 PM EST - 11 days ago

Celcuity Appoints Charles Romp to its Board of Directors

Feb 4, 2026, 7:05 AM EST - 19 days ago

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 22, 2026, 10:26 AM EST - 4 weeks ago

These 20 stocks are strong choices for momentum investors

BE COGT FBYD FRGE INBX KOD LITE

Jan 20, 2026, 7:30 AM EST - 4 weeks ago

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Dec 24, 2025, 11:25 AM EST - 2 months ago

Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond

Dec 11, 2025, 2:35 PM EST - 2 months ago

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Nov 28, 2025, 7:30 AM EST - 3 months ago

Celcuity: From Speculative Bet To Pre-Commercial Powerhouse

Nov 26, 2025, 4:05 PM EST - 3 months ago

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Nov 26, 2025, 7:05 AM EST - 3 months ago

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

Nov 17, 2025, 4:05 PM EST - 3 months ago

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Nov 12, 2025, 8:01 PM EST - 3 months ago

Celcuity Inc. (CELC) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:01 PM EST - 3 months ago

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:05 AM EST - 3 months ago

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Nov 4, 2025, 7:05 AM EST - 3 months ago

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

Oct 21, 2025, 5:41 PM EDT - 4 months ago

Celcuity: Updated Gedatolisib Data Bodes Well For Mutant-Type Cohort Results

Oct 20, 2025, 5:05 PM EDT - 4 months ago

Celcuity Inc. (CELC) Discusses Additional Results From Phase III VIKTORIA-1 Trial and Insights Into PAM Pathway Targeting Transcript

Oct 20, 2025, 9:42 AM EDT - 4 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CRMD RANI RAPT

Oct 18, 2025, 4:30 AM EDT - 4 months ago

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Oct 18, 2025, 4:30 AM EDT - 4 months ago

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Oct 18, 2025, 4:30 AM EDT - 4 months ago

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Oct 8, 2025, 11:22 AM EDT - 4 months ago

Celcuity: Blink And You Missed It

Sep 22, 2025, 9:15 AM EDT - 5 months ago

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Sep 9, 2025, 4:01 PM EDT - 5 months ago

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Aug 27, 2025, 4:05 PM EDT - 6 months ago

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Aug 15, 2025, 11:40 AM EDT - 6 months ago

Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:01 PM EDT - 6 months ago

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:05 AM EDT - 7 months ago

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Jul 30, 2025, 3:42 PM EDT - 7 months ago

Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst

Jul 30, 2025, 6:30 AM EDT - 7 months ago

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Jul 29, 2025, 6:40 AM EDT - 7 months ago

Celcuity: What's Happening With CELC Stock?

Jul 28, 2025, 4:02 PM EDT - 7 months ago

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Jul 28, 2025, 3:02 PM EDT - 7 months ago

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Jul 28, 2025, 7:49 AM EDT - 7 months ago

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Jul 28, 2025, 7:00 AM EDT - 7 months ago

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Jul 25, 2025, 4:05 PM EDT - 7 months ago

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Jul 24, 2025, 4:01 PM EDT - 7 months ago

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Jul 14, 2025, 7:05 AM EDT - 8 months ago

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Jun 30, 2025, 7:05 AM EDT - 8 months ago

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

May 21, 2025, 7:05 AM EDT - 9 months ago

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

May 14, 2025, 9:36 PM EDT - 10 months ago

Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 10 months ago

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 7:05 AM EDT - 10 months ago

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

Apr 1, 2025, 7:05 AM EDT - 11 months ago

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Mar 31, 2025, 10:50 PM EDT - 11 months ago

Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:01 PM EDT - 11 months ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Feb 25, 2025, 7:05 AM EST - 1 year ago

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Feb 19, 2025, 6:24 PM EST - 1 year ago

Celcuity's High-Stakes Oncology Bet Is Underappreciated

Dec 11, 2024, 7:05 AM EST - 1 year ago

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

CharlieeMungerTWITS Feb. 21 at 1:20 AM

$CELC I’m coming I’m coming baby. Don’t worry

0 · Reply

Savon13 Feb. 18 at 3:58 PM

$IBRX feels good to be in under $6. Hoping this goes the same way as $CELC

1 · Reply

DipinDipout Feb. 17 at 9:50 PM

$CELC keep these SLS garbage posts out of here! Those folks are sooooo desperate, avoid at all costs! Bunch of kids hoping to be billionaires while snacking in their parents basements!

1 · Reply

WallStreetBuyDip Feb. 16 at 11:25 PM

0 · Reply

WallStreetBuyDip Feb. 16 at 10:59 PM

0 · Reply

BIOTECH_GURU Feb. 16 at 8:00 PM

$CELC this is how i feel about $SLS Lots of upside potential. Hoping for $50 will take $25.

2 · Reply

UgoGreg Feb. 16 at 7:27 PM

$CELC https://youtu.be/ygBN8MilTyc

0 · Reply

Florestan Feb. 16 at 12:54 PM

$CELC time flies eh?

0 · Reply

Dark_Horse_Investments Feb. 13 at 9:33 PM

0 · Reply

SuperGreenToday Feb. 12 at 12:40 AM

0 · Reply

widgeon7 Feb. 11 at 8:56 PM

$CELC More from the CEO today: "the doctors who have worked with the drug, you know, investigators are unbelievably optimistic about the role this drug can play"

0 · Reply

widgeon7 Feb. 11 at 8:54 PM

$CELC CEO today on Guggenheim conf: "We reported a hazard ratio of 0.24, which translates to a 76% reduction of risk of progression or death, and that level of benefit hadn't ever been seen before compared to endocrine therapy. The incremental improvement in PFS or multiple relative to endocrine therapy of nearly 5-fold was unprecedented"

0 · Reply

Dark_Horse_Investments Feb. 11 at 7:00 PM

$CELC very good call today, guggenheim : a very good crash course to understanding how gedatolisib works providing a comprehensive blockade of the entire PI3K/AKT/mTOR (PAM) pathway, a critical driver of cancer cell growth (prevalent in breast, prostate, renal and endometrial cancers)... take a stab, listen to it as background noise. https://event.summitcast.com/view/kbtj9ZAiVkB78KPZiu5dZ9/guest_book?session_id=2Q8oLmGM98qWAwr5LXWSr8

0 · Reply

Breakoutstockmoves Feb. 10 at 6:14 AM

$ABP Breast cancer phase 1 starts takes this to $100M+ market cap like $GLSI Successful phase 1 and you are talking $1B+ market cap like $CELC Successful ph2 and it’s $3B as they go into phase 3. Then sky is the limit with manufacturing. If celltrion can already cover the hard part then wow. We have seen magic runs over and over. Should be interesting to see how this runs over the next few days and weeks and months as Ph1 begins.

1 · Reply

Quantumup Feb. 4 at 7:09 PM

Wolfe Research said in its $CELC (Outperform; PT $110) note: PersevERAing through an External Catalyst $RHHBY $RLAY $AZN $PFE NVS LLY Wolfe Research additionally said: We think investors should be careful when extrapolating giredestrant's prior success to persevERA as it is a more difficult trial to beat, even after acknowledging that giredestrant is a good drug. We'd be buyers of CELC on any weakness related to the external catalyst.

0 · Reply

SuperGreenToday Feb. 2 at 3:29 PM

$CELC Share Price: $110.89 Contract Selected: May 15, 2026 $110 Calls Buy Zone: $16.06 – $19.84 Target Zone: $30.23 – $36.95 Potential Upside: 78% ROI Time to Expiration: 101 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

DipinDipout Feb. 2 at 1:23 PM

$CELC Thoughts on the squeeze here?

1 · Reply

SuperGreenToday Jan. 30 at 2:58 PM

$CELC Share Price: $112.28 Contract Selected: May 15, 2026 $110 Calls Buy Zone: $16.37 – $20.22 Target Zone: $29.64 – $36.23 Potential Upside: 71% ROI Time to Expiration: 104 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Johnny_Lever Jan. 27 at 9:34 PM

$CELC Broke out of the channel.

0 · Reply

Quantumup Jan. 26 at 11:25 AM

Oppenheimer⬆️ $RLAY: We are upgrading shares of Relay Therapeutics to Outperform (prior Perform) — with a $14 PT — because we believe that gedatolisib's upcoming VIKTORIA-1 readout could be a tailwind for mutant-selective inhibitors like zovegalisib. [ $CELC $NVS ] Bottom line: We believe VIKTORIA-1 will underperform expectations, and may even fail. We think anything less than "teenage" mPFS for the gedatolisib triplet would create a beatable bar for Relay, who is developing a competing triplet with zovegalisib. We think gedatolisib looks a lot like everolimus, and everolimus underperforms in PI3K. Relay shares have struggled since October when VIKTORIA-1's wild-type cohort came out and exceeded expectations. We believe that duplicating that success in PI3K-mutant patients will be more challenging for gedatolisib, especially given the recent precedent set by alpelisib in the EPIK-B5 trial (7.4-months mPFS).

1 · Reply

Merlintrader Jan. 25 at 10:42 PM

$CELC https://www.merlintrader.com/celc-celcuity-inc/

0 · Reply

theflynews Jan. 25 at 6:52 PM

Short Report: Celcuity short interest continues to grow - $CELC - https://legacy.thefly.com/permalinks/entry.php/CELCid4277022?1769366358C3

1 · Reply

Market Cap	4.85B
Revenue (ttm)	0.00
Net Income (ttm)	-111.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.07

Volume	406,016
Avg Vol	786,424
Day's Range	N/A - N/A
Shares Out	46.27M
Stochastic %K	57%
Beta	0.36
Analysts	Strong Sell
Price Target	$114.20